Atherosclerosis
Volume 185, Issue 2 , Pages 246-253 , April 2006

Human monoclonal IgG anticardiolipin antibodies induce nitric oxide synthase expression

  • J. Delgado Alves

      Affiliations

    • Department of Pharmacology, Faculty of Medical Sciences, New University of Lisbon, Campo Mártires da Pátria 130, 1169-056 Lisboa, Portugal
    • Corresponding Author InformationCorresponding author. Tel.: +351 21 880 3035; fax: +351 218 803 083.
    • ,
  • B.R. Clapp

      Affiliations

    • Centre for Clinical Pharmacology, University College London, London, UK
    • ,
  • R. Stidwill

      Affiliations

    • Intensive Care, University College London, London, UK
    • ,
  • P.P. Chen

      Affiliations

    • Department of Medicine, Division of Rheumatology, University of California, Los Angeles, CA, USA
    • ,
  • A.D. Hingorani

      Affiliations

    • Centre for Clinical Pharmacology, University College London, London, UK
    • ,
  • M. Singer

      Affiliations

    • Intensive Care, University College London, London, UK
    • ,
  • D.A. Isenberg

      Affiliations

    • Centre for Rheumatology, University College London, London, UK

Received 15 October 2004 ,Revised 10 June 2005 ,Accepted 21 June 2005.

References 

  1. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood. 1994;84:2854–2867
  2. Arnout J, Vermylen J. Mechanism of action of beta2-glycoprotein I-dependent lupus anticoagulants. Lupus. 1998;7(Suppl. 2):S23–S28
  3. Roubey RA. Mechanisms of autoantibody-mediated thrombosis. Lupus. 1998;7(Suppl. 2):S114–S119
  4. Khamashta MA, Hughes GRV. The antiphospholipid antibody syndrome. In:  Maddison PJ,  Isenberg DA,  Woo P,  Glass DN editor. Oxford textbook of rheumatology. Oxford: Oxford Medical Publications; 1998;p. 1202–1216
  5. Joseph JE, Harrison P, Mackie IJ, et al. Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Lupus. 1998;7(Suppl. 2):S48–S51
  6. Dobado-Berrios PM, Lopez-Pedrera C, Velasco F, et al. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost. 1999;82:1578–1582
  7. Levy RA, Avvad E, Oliveira J, et al. Placental pathology in antiphospholipid syndrome. Lupus. 1998;7(Suppl. 2):S81–S85
  8. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun. 2000;15:237–240
  9. Ames PR, Tommasino C, Alves J, et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus. 2000;9:688–695
  10. Iuliano L, Pratico D, Ferro D, et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood. 1997;90:3931–3935
  11. Ames PR, Nourooz-Zadeh J, Tommasino C, et al. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost. 1998;79:447–449
  12. Delgado AJ, Ames PR, Donohue S, et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2002;46:2686–2694
  13. Zhu M, Olee T, Le DT, et al. Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol. 1999;105:102–109
  14. Giovannoni G, Land JM, Keir G, et al. Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem. 1997;34:193–198
  15. Freedman JE, Loscalzo J, Barnard MR, et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997;100:350–356
  16. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998;18:1771–1779
  17. Lu JL, Schmiege LM, Kuo L, et al. Downregulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide. Biochem Biophys Res Commun. 1996;225:1–5
  18. Parker JL, Adams HR. Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia coli endotoxemia. Circ Res. 1993;72:539–551
  19. Delgado Alves J, Davies NA, Mason L, et al. Anticardiolipin antibody is associated with decreased paraoxonase activity and serum nitric oxide in a mouse model. Arthritis Rheum. 2002;46(Suppl. 9):S230
  20. Porta C, Buggia I, Bonomi I, et al. Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies-related conditions and in thrombotic thrombocytopenic purpura. Thromb Haemost. 1997;78:965–967
  21. Del Papa N, Guidali L, Spatola L, et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheum. 1995;13:179–185
  22. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870–2878
  23. Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol. 2002;282:C395–C402

PII: S0021-9150(05)00398-9

doi: 10.1016/j.atherosclerosis.2005.06.044

Atherosclerosis
Volume 185, Issue 2 , Pages 246-253 , April 2006

Article Tools

* Image Usage & Resolution